Background Carbon nanomaterials are a growing family of materials featuring unique
physicochemical properties, and their widespread application is accompanied by increasing …

Glioblastoma (GBM) is characterized by aggressive growth and high rates of recurrence.
Despite the advancements in conventional therapies, the prognosis for GBM patients …

Due to their biocompatibility, non-toxicity, and surface-conjugation capabilities, liposomes
are effective nanocarriers that can encapsulate chemotherapeutic drugs and facilitate …

After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce
immune responses. As such, autologous DCs generated ex vivo have been pulsed with …

Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …

Cancer nanovaccines as one of immunotherapeutic approaches are able to attack tumors by
stimulating tumor-specific immunological responses. However, there still exist multiple …

Research into the immunological processes implicated in cancer has yielded a basis for the
range of immunotherapies that are now considered the fourth pillar of cancer treatment …

Purpose Immunologic targeting of tumor-specific gene mutations may allow precise
eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III …

Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5‐
year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique …

Background This study evaluated the safety and immune responses to an autologous
dendritic cell vaccine pulsed with class I peptides from tumor-associated antigens (TAA) …